Search results | cubist

Reports

Partnering Agreements with Cubist

The Partnering Agreements with Cubist report provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies.

Insights

Cubist Pharma, the next acquisition target for big pharmaceuticals

The timing may be right for a takeover of Cubist Pharmaceuticals.

Cubist: M&A activity 2009-2014

Cubist has acquired a few companies in the last five years with its biggest purchase of $800 million of Optimer Pharmaceuticals.      

Cubist Pharmaceuticals – Shaping developments in antibiotics

Cubist Pharmaceuticals is a biopharmaceutical company developing and commercializing medications for acute care in hospitals and surgical environments.

Cubist: Partnering activity 2009-2014

Cubist, a leading biopharmaceutical company focusses in the discovery, development and commercialization of novel acute care therapies.

Biotech rumor mill: AstraZeneca, Astellas, Cubist among pharma acquisition bidders for Optimer

Rumors swirl about the possibility of Optimer Pharmaceuticals being an acquisition target in the coming weeks

Cubist: Company profile

Cubist, a leading biopharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Isis Pharmaceuticals: So many partnerships, so little time

Isis Pharmaceuticals is an antisense drug discovery technology company developing therapies for a number of serious diseases.

Current Agreements Deal Analysis Update : July 2014

This month we provide you with an overview of life science deal making activity, covering partnering, M&A and financing in June 2014.

Preclinical stage partnering

Preclinical stage partnering refers to a commercial deal or alliance signed when a compound or product…

Deal rumors surround Optimer: several big pharma interested in acquisition?

Acquisition rumours fly as GlaxoSmithKline, Astellas Cubist and AstraZeneca said to be interested in Optimer Pharmaceuticals takeover

Events

Sorry, your search returned no results.


Deals

Merck acquires Cubist Pharmaceuticals for $9.5bn

Merck and Cubist Pharmaceuticals have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share in cash, which represents a 35 percent premium to Cubist’s average stock price for the most recent five trading days.

Cubist expands financing round to $800 million offering

Cubist Pharmaceuticals has upped the size of its financing offering of convertible notes to as much at $800 million, including overallotments, to pay for its acquisition of Optimer Pharmaceuticals.

Cubist announces financing of $600m in convertible senior notes

Big biotech, Cubist Pharmaceuticals, announced its intention to commence a financing offering, subject to market and other conditions, of $600 million in convertible senior unsecured notes that are expected to be issued in two $300 million series

Cubist seals merger and acquisition activity with Optimer buy

Cubist Pharmaceuticals and Optimer Pharmaceuticals seal merger and acquisition activity under which Cubist will acquire all of the outstanding shares of Optimer common stock for $10.75 per share in cash, or approximately $535 million on a fully diluted basis

Cubist creates M&A news with Trius Therapeutics buy

M&A news: Cubist Pharmaceuticals,  and Trius Therapeutics have signed a definitive agreement under which Cubist will acquire all outstanding shares of Trius for $13.50 per share in cash or approximately $707 million on a fully diluted basis

Biotech rumor mill: AstraZeneca, Astellas, Cubist among pharma acquisition bidders for Optimer

Rumors swirl about the possibility of Optimer Pharmaceuticals being an acquisition target in the coming weeks

Cubist Pharmaceuticals in pharma licensing pact with Astellas Pharma

Cubist Pharmaceuticals and Astellas Pharma have entered into a pharma licensing agreement under which Cubist obtains the rights to ceftolozane in certain Asia-Pacific and Middle East territories from Astellas.

Cubist Pharma explores biotech partnering with Adynxx

Cubist Pharmaceuticals, a big biotech company, and Adynxx have entered into an option agreement under which Cubist explores biotech partnering with Adynxx.

Cepheid signs pharma deal with 3 big pharmas

Cepheid announced a new pharma deal with AstraZeneca, Cubist Pharmaceuticals, and GSK intended to promote transformational change in infectious disease therapy.

Deal rumors surround Optimer: several big pharma interested in acquisition?

Acquisition rumours fly as GlaxoSmithKline, Astellas Cubist and AstraZeneca said to be interested in Optimer Pharmaceuticals takeover

cpbannerad300x150new2gif
rauconbadgejpg
e78banner300x150animgif
cpbannerad300x150new2gif
rauconbadgejpg
amsbanner300x150jpg